Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Thoracic Oncology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e318283558ePMID 23392229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Mutations in the epidermal growth factor receptor

  2012cited by this paper
• Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.

  2012influential reference
• Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).

  2012cited by this paper
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012cited by this paper
• EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

  2012cited by this paper
• Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

  2011cited by this paper
• Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

  2011cited by this paper
• Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH

  2011cited by this paper
• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

  2010cited by this paper
• MET receptor sequence variants R970C and T992I lack transforming capacity.

  2010cited by this paper
• Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

  2010cited by this paper
• A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

  2010cited by this paper
• PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

  2010cited by this paper
• Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer

  2010cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology 3 CA Mutation Uncouples Tumor Growth and Cyclin D 1 R ulation from MEK / ERK and Mutant KRAS Signaling

  2010cited by this paper
• Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

  2009cited by this paper
• Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

  2009cited by this paper
• Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

  2009cited by this paper
• Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

  2009cited by this paper
• Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.

  2008cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

  2008cited by this paper
• PIK3CA mutation and amplification in human lung cancer

  2007cited by this paper
• High-throughput oncogene mutation profiling in human cancer

  2007cited by this paper
• Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.

  2007cited by this paper
• Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline

  2007cited by this paper
• FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

  2006cited by this paper
• FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

  2006cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Oncogenic mutations of PIK3CA in human cancers.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Oncogenic Mutations of PIK3CA in Human Cancers

  2004cited by this paper
• The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  2004cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• AJCC Cancer Staging Manual. 6th ed

  2002cited by this paper
• Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.

  2002cited by this paper

• Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia.

  2025cites this paper
• Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses

  2023influential citation
• CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-Resistant Lung Cancer

  2021cites this paper
• Molecular and Biological Basis of Lung Cancer-Part I

  2020cites this paper
• Targeted Therapies For Treatment of Lung Cancer – Recent Advances

  2020cites this paper
• TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer.

  2019cites this paper
• Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis

  2018cites this paper
• An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer

  2018cites this paper
• RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers

  2018cites this paper
• EGFR–Co‐Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors

  2017cites this paper
• Recent advances in the management of non-small cell lung cancer

  2017cites this paper
• Screening for ROS1 gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target

  2017cites this paper
• Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey

  2016cites this paper
• Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations

  2016cites this paper
• MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.

  2016cites this paper
• The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

  2016cites this paper
• Importance of Mutation Analysis in Anti‐Cancer Therapy

  2016cites this paper
• Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer

  2016cites this paper
• Diagnostic Mutation Profiling and Validation of Non–Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform

  2015cites this paper
• Somatic DNA mutation analysis in targeted therapy of solid tumours.

  2015cites this paper
• BRAF mutations in non-small cell lung cancer.

  2015cites this paper
• The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer.

  2015cites this paper
• Genomic medicine and targeted therapy for solid tumors

  2015cites this paper
• Thank You to Reviewers

  2015cites this paper
• L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report.

  2015cites this paper
• PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

  2015cites this paper
• L 858 R ‐ positive lung adenocarcinoma with KRAS G 12 V , EGFR T 790 M and EGFR L 858 R mutations : A case report

  2015cites this paper
• Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH

  2014cites this paper
• Molecular Targets in the Treatment of Non—Small-Cell Lung Cancer: Is There Hope on the Horizon?

  2014cites this paper
• Detecting ALK Gene Rearrangements in Lung Cancer Cytology Specimens

  2014cites this paper
• Science and mechanism of action of targeted therapies in cancer treatment.

  2014cites this paper
• Intertumor heterogeneity of non‐small‐cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics

  2014cites this paper
• Concurrent Oncogene Mutation Profile in Chinese Patients With Stage Ib Lung Adenocarcinoma

  2014cites this paper
• Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single‐institute study

  2014cites this paper
• Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer

  2014cites this paper
• Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma.

  2014cites this paper
• Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells

  2014cites this paper
• Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.

  2013cites this paper
• Molecular biology of lung cancer.

  2013cites this paper
• Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

  2013cites this paper
• Molecular pathology in lung cancer

  2013cites this paper
• EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma

  2013cites this paper